Motor Neuron Disease Clinic

Ospedaliera di Padova, University of Padova

The Motor Neuron Disease (MND) Clinic of the University of Padova is a referral center for motor neuron disorders in the North-East area of Italy. Both patient care and research are primary missions of the Clinic.

universita de Paduva klein
University of Padova

Our MND Clinic is a hospital-based and academic facility of the Azienda Ospedaliera of Padova, University of Padova, Italy. Linked to the Neuromuscular Unit, it is a referral center for motor neuron disorders in the North-East area of Italy. The full aspects of motor neuron diseases, from diagnosis to advanced stage disease care, are covered.  The Clinic Team is a multi-disciplinary group including Neurologists, Neurology residents or fellows working with them, along with specialized healthcare providers for symptom management and treatment (speech language pathologist, psychologists, nurses, and case manager). The research program of the Clinic focuses on understanding the mechanisms of motor neuron diseases and their secondary conditions, improving care and developing therapies. National and international collaborations are currently ongoing. A biobank of tissues and DNAs from hundreds of MND patients is also available for both diagnostic and research purposes.

Contact
Location
Clinica Neurologica, via Giustiniani 5, 35128 Padova

Our Specialists

Gianni Sorarù

Clinical expert and Principal investigator of clinical trials

Dr. Gianni Sorarù is an associate professor of Neurology at the Department […]

Gianni Sorarù
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more